View ValuationCarlsmed 향후 성장Future 기준 점검 2/6Carlsmed은 연간 수입과 매출이 각각 0.5%와 33.7% 증가할 것으로 예상되고 EPS는 연간 11.7%만큼 증가할 것으로 예상됩니다.핵심 정보0.5%이익 성장률11.71%EPS 성장률Medical Equipment 이익 성장16.1%매출 성장률33.7%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트27 May 2026최근 향후 성장 업데이트공시 • May 07Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2026Carlsmed, Inc. raised earnings guidance for the full year 2026. For the year, company expected revenue to be in the range of $72 to $77 million, representing growth of 48% at the midpoint of the range over 2025. This compares to prior guidance of $70 to $75 million.공시 • Feb 26Carlsmed, Inc. Provides Revenue Guidance for the Year 2026Carlsmed, Inc. provided Revenue guidance for the year 2026. Revenue for 2026 is expected to be in the range of $70 to $75 million, representing growth at the midpoint of the range of 44% over 2025.공시 • Nov 07Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2025Carlsmed, Inc. raised earnings guidance for the full year 2025. For the year, the company's revenue for the full year 2025 is expected to be in the range of $49.0 million to $50.0 million, representing growth of 80% to 84% over 2024. This compares to prior guidance of $45.5 million to $47.5 million.공시 • Aug 29Carlsmed, Inc. Provides Earnings Guidance for the Full Year 2025Carlsmed, Inc. provided earnings guidance for the full year 2025. For the year, the company expects revenue to be in the range of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024.모든 업데이트 보기Recent updates공시 • May 07Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2026Carlsmed, Inc. raised earnings guidance for the full year 2026. For the year, company expected revenue to be in the range of $72 to $77 million, representing growth of 48% at the midpoint of the range over 2025. This compares to prior guidance of $70 to $75 million.Reported Earnings • May 06First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$0.32 loss per share. Revenue: US$16.1m (up 58% from 1Q 2025). Net loss: US$8.70m (loss widened 38% from 1Q 2025). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.공시 • Apr 23Carlsmed, Inc., Annual General Meeting, Jun 03, 2026Carlsmed, Inc., Annual General Meeting, Jun 03, 2026. Location: at the offices of morrison & foerster llp, located at 12531 high bluff drive, suite 200, ca 92130, san diego, United States공시 • Apr 14Carlsmed, Inc. to Report Q1, 2026 Results on May 05, 2026Carlsmed, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 05, 2026Recent Insider Transactions Derivative • Mar 03Co-Founder notifies of intention to sell stockMichael Cordonnier intends to sell 198k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of March. If the sale is conducted around the recent share price of US$13.29, it would amount to US$2.6m. For the year to December 2024, Michael's total compensation was 70% salary and 30% non-salary. Since June 2025, Michael's direct individual holding has increased from 221.46k shares to 1.24m. Company insiders have collectively bought US$8.1m more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Feb 26Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$2.13 loss per share. Revenue: US$50.5m (up 86% from FY 2024). Net loss: US$30.2m (loss widened 22% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 12%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US.공시 • Feb 26Carlsmed, Inc. Provides Revenue Guidance for the Year 2026Carlsmed, Inc. provided Revenue guidance for the year 2026. Revenue for 2026 is expected to be in the range of $70 to $75 million, representing growth at the midpoint of the range of 44% over 2025.공시 • Feb 19Carlsmed, Inc. Announces First Corra™ Personalized Cervical Plating ProcedureCarlsmed, Inc. announced the first personalized cervical plating procedure using the corra Cervical Plating System, the latest addition to its portfolio of personalized spine surgery solutions. The procedure, which was performed by Dr. Aaron Clark at the University of California San Francisco (UCSF), represents an important milestone as the Company prepares for the planned commercial launch of the corra™? system later this year. The corra™? Cervical Plating System is designed to stabilize the cervical spine during fusion procedures using patient-specific plates tailored to each individual's anatomy and surgical plan. Utilizing Carlsmed's digital surgery ecosystem, key anatomical aspects including screw positioning and plate curvature are tailored pre-operatively to each vertebral level, helping support consistent fixation and precise alignment for Anterior Cervical Discectomy and Fusion (ACDF) procedures. When used in conjunction with the aprevo®? cervical planning and interbody fusion devices, the corra™? Personalized Plating System can provide anatomical fit and fixation for patients. Data from the clinical evaluation will inform continued product refinement as Carlsmed prepares for broader market introduction. The Company expects to conduct additional evaluations in the coming months and anticipates commercial launch later this year.공시 • Feb 12Carlsmed, Inc. to Report Q4, 2025 Results on Feb 25, 2026Carlsmed, Inc. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026공시 • Feb 11Carlsmed, Inc. Announces First Aprevo Bi-Lateral Posterior Lumbar Interbody Fusion ProcedureCarlsmed, Inc. announced the successful completion of the first posterior lumbar spine surgery using the Company's aprevo Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado. Carlsmed's Bi-lateral Posterior Fusion System integrates seamlessly with the Company's broader aprevo platform technology, which combines proprietary AI-enabled software and clinical intelligence to deliver personalized surgical strategies and preoperative planning across a range of spinal pathologies. The Company expects to commercially launch the system later this year.새로운 내러티브 • Feb 08Personalized Spine Surgery Will Reshape A US$13b Market Over The Long TermCatalysts About Carlsmed Carlsmed provides a digital surgery platform and patient specific 3D printed spine implants for lumbar and cervical fusion procedures. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • Jan 23AI Spine Surgery And Personalized Implants Will Transform Long-Term Earnings PotentialCatalysts About Carlsmed Carlsmed provides a digital surgery platform and patient specific spine implants designed to improve alignment and reduce revision procedures. What are the underlying business or industry changes driving this perspective?공시 • Jan 07Carlsmed Aprevo Lumbar 2-Year Data Published in Global Spine JournalCarlsmed, Inc. announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically designed interbody implants significantly reduces mechanical complication-related reoperations in complex adult spinal deformity (ASD) surgery. The study compared 2-year revision rates among ASD patients receiving Carlsmed's aprevo®? personalized interbody implants with revision data from a similar patient cohort receiving conventional stock implants. The comparator cohort was drawn from the multicenter dataset of the International Spine Study Group, which is comprised of senior spine surgeons dedicated to advancing the treatment of adult spinal deformity. Patients treated with aprevo®? experienced significantly fewer revisions due to mechanical complications, showing a revision rate of 4.3% (n=115) compared with 16.6% (n=997) using stock devices (pp).Board Change • Dec 31Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Kevin O’Boyle was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Dec 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 5.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$33m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).Seeking Alpha • Nov 29Carlsmed: Back To Where We StartedSummary Carlsmed offers AI-enabled personalized spine surgery solutions, showing strong revenue growth and expanding its addressable market. Carlsmed´s sales nearly doubled year-over-year, with 2025 revenue guidance raised to $49.5 million, but operating losses have also increased substantially. Despite sequential revenue growth and conservative guidance, Carlsmed´s lack of operating leverage and reliance on a single product remain concerns. I remain cautious and prefer to watch progress from the sidelines, given ongoing operating losses, but curious to update my take. Read the full article on Seeking AlphaReported Earnings • Nov 07Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.40 loss per share. Net loss: US$8.53m (flat on 3Q 2024). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 5.3%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.공시 • Nov 07Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2025Carlsmed, Inc. raised earnings guidance for the full year 2025. For the year, the company's revenue for the full year 2025 is expected to be in the range of $49.0 million to $50.0 million, representing growth of 80% to 84% over 2024. This compares to prior guidance of $45.5 million to $47.5 million.공시 • Oct 24Carlsmed, Inc. to Report Q3, 2025 Results on Nov 06, 2025Carlsmed, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025공시 • Sep 30Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary, Effective September 29, 2025Carlsmed, Inc. announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective September 29, 2025. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance. Ms. Kamocsay brings more than two decades of corporate legal experience as in-house counsel across life science and technology sectors at Akoya Biosicences, Rubius Therapeutics, Inc. and Progress Software Corporation. Prior to Akoya, Ms. Kamocsay served as General Counsel and Corporate Secretary of Rubius Therapeutics, Inc., where she was responsible for overseeing and managing all of the company’s legal affairs. Before Rubius, she served as Associate General Counsel and Assistant Secretary at Progress Software Corporation, where she managed the company’s corporate, securities law, and M&A initiatives. Ms. Kamocsay began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she provided counsel to public and private company clients in the biotechnology and pharmaceutical industries on M&A, securities law, and corporate governance matters. Ms. Kamocsay holds a B.A. in History from the University of California, Los Angeles and a J.D. from Northeastern University School of Law.Reported Earnings • Aug 31Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: US$1.47 loss per share. Net loss: US$6.77m (flat on 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.공시 • Aug 29Carlsmed, Inc. Provides Earnings Guidance for the Full Year 2025Carlsmed, Inc. provided earnings guidance for the full year 2025. For the year, the company expects revenue to be in the range of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024.New Risk • Aug 18New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 8.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 8.1% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$38m net loss in 3 years).공시 • Aug 14Carlsmed, Inc. to Report Q2, 2025 Results on Aug 28, 2025Carlsmed, Inc. announced that they will report Q2, 2025 results After-Market on Aug 28, 2025공시 • Jul 29Carlsmed's Aprevo Powers First Personalized Cervical Spine SurgeryCarlsmed, Inc. announced the successful completion of the first aprevo cervical procedure on July 14, 2025 by Joseph Osorio, MD, PhD, Chief of Spine Surgery in the Department of Neurological Surgery at UC San Diego (UCSD) Health in San Diego, CA. The aprevo devices are designed to match the unique anatomical and alignment needs of each patient through Carlsmed's proprietary AI-powered surgical planning platform and digital production system.Recent Insider Transactions • Jul 27Independent Director recently bought US$7.0m worth of stockOn the 24th of July, Jonathan Root bought around 467k shares on-market at roughly US$15.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$8.1m more in shares than they have sold in the last 12 months.공시 • Jul 23Carlsmed, Inc. has completed an IPO in the amount of $100.5 million.Carlsmed, Inc. has completed an IPO in the amount of $100.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,700,000 Price\Range: $15 Discount Per Security: $1.05 Transaction Features: Sponsor Backed Offering이익 및 매출 성장 예측NasdaqGS:CARL - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028146-31N/AN/A412/31/2027106-42N/AN/A512/31/202675-40N/AN/A53/31/202656-33-35-34N/A12/31/202551-30-30-29N/A9/30/202545-26-29-28N/A6/30/202538-26-28-27N/A3/31/202532-26-27-26N/A12/31/202427-25-26-25N/A12/31/202314-19-18-17N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CARL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: CARL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: CARL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: CARL 의 수익(연간 33.7%)이 US 시장(연간 11.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: CARL 의 수익(연간 33.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CARL의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/28 22:08종가2026/05/28 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Carlsmed, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Travis SteedBofA Global ResearchTravis SteedBofA Global ResearchMichael GormanBTIG4명의 분석가 더 보기
공시 • May 07Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2026Carlsmed, Inc. raised earnings guidance for the full year 2026. For the year, company expected revenue to be in the range of $72 to $77 million, representing growth of 48% at the midpoint of the range over 2025. This compares to prior guidance of $70 to $75 million.
공시 • Feb 26Carlsmed, Inc. Provides Revenue Guidance for the Year 2026Carlsmed, Inc. provided Revenue guidance for the year 2026. Revenue for 2026 is expected to be in the range of $70 to $75 million, representing growth at the midpoint of the range of 44% over 2025.
공시 • Nov 07Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2025Carlsmed, Inc. raised earnings guidance for the full year 2025. For the year, the company's revenue for the full year 2025 is expected to be in the range of $49.0 million to $50.0 million, representing growth of 80% to 84% over 2024. This compares to prior guidance of $45.5 million to $47.5 million.
공시 • Aug 29Carlsmed, Inc. Provides Earnings Guidance for the Full Year 2025Carlsmed, Inc. provided earnings guidance for the full year 2025. For the year, the company expects revenue to be in the range of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024.
공시 • May 07Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2026Carlsmed, Inc. raised earnings guidance for the full year 2026. For the year, company expected revenue to be in the range of $72 to $77 million, representing growth of 48% at the midpoint of the range over 2025. This compares to prior guidance of $70 to $75 million.
Reported Earnings • May 06First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$0.32 loss per share. Revenue: US$16.1m (up 58% from 1Q 2025). Net loss: US$8.70m (loss widened 38% from 1Q 2025). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.
공시 • Apr 23Carlsmed, Inc., Annual General Meeting, Jun 03, 2026Carlsmed, Inc., Annual General Meeting, Jun 03, 2026. Location: at the offices of morrison & foerster llp, located at 12531 high bluff drive, suite 200, ca 92130, san diego, United States
공시 • Apr 14Carlsmed, Inc. to Report Q1, 2026 Results on May 05, 2026Carlsmed, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 05, 2026
Recent Insider Transactions Derivative • Mar 03Co-Founder notifies of intention to sell stockMichael Cordonnier intends to sell 198k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of March. If the sale is conducted around the recent share price of US$13.29, it would amount to US$2.6m. For the year to December 2024, Michael's total compensation was 70% salary and 30% non-salary. Since June 2025, Michael's direct individual holding has increased from 221.46k shares to 1.24m. Company insiders have collectively bought US$8.1m more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Feb 26Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$2.13 loss per share. Revenue: US$50.5m (up 86% from FY 2024). Net loss: US$30.2m (loss widened 22% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 12%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US.
공시 • Feb 26Carlsmed, Inc. Provides Revenue Guidance for the Year 2026Carlsmed, Inc. provided Revenue guidance for the year 2026. Revenue for 2026 is expected to be in the range of $70 to $75 million, representing growth at the midpoint of the range of 44% over 2025.
공시 • Feb 19Carlsmed, Inc. Announces First Corra™ Personalized Cervical Plating ProcedureCarlsmed, Inc. announced the first personalized cervical plating procedure using the corra Cervical Plating System, the latest addition to its portfolio of personalized spine surgery solutions. The procedure, which was performed by Dr. Aaron Clark at the University of California San Francisco (UCSF), represents an important milestone as the Company prepares for the planned commercial launch of the corra™? system later this year. The corra™? Cervical Plating System is designed to stabilize the cervical spine during fusion procedures using patient-specific plates tailored to each individual's anatomy and surgical plan. Utilizing Carlsmed's digital surgery ecosystem, key anatomical aspects including screw positioning and plate curvature are tailored pre-operatively to each vertebral level, helping support consistent fixation and precise alignment for Anterior Cervical Discectomy and Fusion (ACDF) procedures. When used in conjunction with the aprevo®? cervical planning and interbody fusion devices, the corra™? Personalized Plating System can provide anatomical fit and fixation for patients. Data from the clinical evaluation will inform continued product refinement as Carlsmed prepares for broader market introduction. The Company expects to conduct additional evaluations in the coming months and anticipates commercial launch later this year.
공시 • Feb 12Carlsmed, Inc. to Report Q4, 2025 Results on Feb 25, 2026Carlsmed, Inc. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026
공시 • Feb 11Carlsmed, Inc. Announces First Aprevo Bi-Lateral Posterior Lumbar Interbody Fusion ProcedureCarlsmed, Inc. announced the successful completion of the first posterior lumbar spine surgery using the Company's aprevo Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado. Carlsmed's Bi-lateral Posterior Fusion System integrates seamlessly with the Company's broader aprevo platform technology, which combines proprietary AI-enabled software and clinical intelligence to deliver personalized surgical strategies and preoperative planning across a range of spinal pathologies. The Company expects to commercially launch the system later this year.
새로운 내러티브 • Feb 08Personalized Spine Surgery Will Reshape A US$13b Market Over The Long TermCatalysts About Carlsmed Carlsmed provides a digital surgery platform and patient specific 3D printed spine implants for lumbar and cervical fusion procedures. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Jan 23AI Spine Surgery And Personalized Implants Will Transform Long-Term Earnings PotentialCatalysts About Carlsmed Carlsmed provides a digital surgery platform and patient specific spine implants designed to improve alignment and reduce revision procedures. What are the underlying business or industry changes driving this perspective?
공시 • Jan 07Carlsmed Aprevo Lumbar 2-Year Data Published in Global Spine JournalCarlsmed, Inc. announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically designed interbody implants significantly reduces mechanical complication-related reoperations in complex adult spinal deformity (ASD) surgery. The study compared 2-year revision rates among ASD patients receiving Carlsmed's aprevo®? personalized interbody implants with revision data from a similar patient cohort receiving conventional stock implants. The comparator cohort was drawn from the multicenter dataset of the International Spine Study Group, which is comprised of senior spine surgeons dedicated to advancing the treatment of adult spinal deformity. Patients treated with aprevo®? experienced significantly fewer revisions due to mechanical complications, showing a revision rate of 4.3% (n=115) compared with 16.6% (n=997) using stock devices (pp).
Board Change • Dec 31Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Kevin O’Boyle was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Dec 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 5.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$33m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).
Seeking Alpha • Nov 29Carlsmed: Back To Where We StartedSummary Carlsmed offers AI-enabled personalized spine surgery solutions, showing strong revenue growth and expanding its addressable market. Carlsmed´s sales nearly doubled year-over-year, with 2025 revenue guidance raised to $49.5 million, but operating losses have also increased substantially. Despite sequential revenue growth and conservative guidance, Carlsmed´s lack of operating leverage and reliance on a single product remain concerns. I remain cautious and prefer to watch progress from the sidelines, given ongoing operating losses, but curious to update my take. Read the full article on Seeking Alpha
Reported Earnings • Nov 07Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.40 loss per share. Net loss: US$8.53m (flat on 3Q 2024). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 5.3%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.
공시 • Nov 07Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2025Carlsmed, Inc. raised earnings guidance for the full year 2025. For the year, the company's revenue for the full year 2025 is expected to be in the range of $49.0 million to $50.0 million, representing growth of 80% to 84% over 2024. This compares to prior guidance of $45.5 million to $47.5 million.
공시 • Oct 24Carlsmed, Inc. to Report Q3, 2025 Results on Nov 06, 2025Carlsmed, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
공시 • Sep 30Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary, Effective September 29, 2025Carlsmed, Inc. announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective September 29, 2025. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance. Ms. Kamocsay brings more than two decades of corporate legal experience as in-house counsel across life science and technology sectors at Akoya Biosicences, Rubius Therapeutics, Inc. and Progress Software Corporation. Prior to Akoya, Ms. Kamocsay served as General Counsel and Corporate Secretary of Rubius Therapeutics, Inc., where she was responsible for overseeing and managing all of the company’s legal affairs. Before Rubius, she served as Associate General Counsel and Assistant Secretary at Progress Software Corporation, where she managed the company’s corporate, securities law, and M&A initiatives. Ms. Kamocsay began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she provided counsel to public and private company clients in the biotechnology and pharmaceutical industries on M&A, securities law, and corporate governance matters. Ms. Kamocsay holds a B.A. in History from the University of California, Los Angeles and a J.D. from Northeastern University School of Law.
Reported Earnings • Aug 31Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: US$1.47 loss per share. Net loss: US$6.77m (flat on 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.
공시 • Aug 29Carlsmed, Inc. Provides Earnings Guidance for the Full Year 2025Carlsmed, Inc. provided earnings guidance for the full year 2025. For the year, the company expects revenue to be in the range of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024.
New Risk • Aug 18New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 8.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 8.1% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$38m net loss in 3 years).
공시 • Aug 14Carlsmed, Inc. to Report Q2, 2025 Results on Aug 28, 2025Carlsmed, Inc. announced that they will report Q2, 2025 results After-Market on Aug 28, 2025
공시 • Jul 29Carlsmed's Aprevo Powers First Personalized Cervical Spine SurgeryCarlsmed, Inc. announced the successful completion of the first aprevo cervical procedure on July 14, 2025 by Joseph Osorio, MD, PhD, Chief of Spine Surgery in the Department of Neurological Surgery at UC San Diego (UCSD) Health in San Diego, CA. The aprevo devices are designed to match the unique anatomical and alignment needs of each patient through Carlsmed's proprietary AI-powered surgical planning platform and digital production system.
Recent Insider Transactions • Jul 27Independent Director recently bought US$7.0m worth of stockOn the 24th of July, Jonathan Root bought around 467k shares on-market at roughly US$15.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$8.1m more in shares than they have sold in the last 12 months.
공시 • Jul 23Carlsmed, Inc. has completed an IPO in the amount of $100.5 million.Carlsmed, Inc. has completed an IPO in the amount of $100.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,700,000 Price\Range: $15 Discount Per Security: $1.05 Transaction Features: Sponsor Backed Offering
